摘要视网膜母细胞瘤(RB)是最常见的儿童眼内恶性肿瘤,严重威胁患儿的视力和生命.我国RB的早期诊断率低、中晚期患者多,眼球摘除率和死亡率居高不下.眼内期RB国际分类是目前指导临床制定RB治疗方案、评价预后的主要依据.不断完善的T(tumor)N (node)M (metastasis)分期有望成为RB的国际通用分期.顺序应用化学治疗联合局部治疗和手术治疗等的综合序列治疗是目前RB治疗的主流方案,可最大限度治愈肿瘤,保留眼球,甚至保存视力.RB治疗的新技术,如动脉介入化学治疗、玻璃体腔注射化学治疗等,进一步提高了RB的治疗效果,尤其提高了眼球保存率.我国应大力推广普及RB国际分期、治疗新技术和综合序列治疗方案,以提高我国RB的总体治疗水平.

abstractsRetinoblastoma (RB) is the most common intraocular malignancy in childhood.It may seriously affect vision,and even threaten the life.The early diagnosis rate of RB in China remains low,and the majority of patients are at late phase with high rates of enucleation and mortality.The International Intraocular Retinoblastoma Classification and TNM staging system are guidances for therapeutic choices and bases for prognosis evaluation.Based on the sequential mnulti-method treatment modality,chemotherapy combined with local therapy is the mainstream in dealing with RB,which may maximize the results of eye saving and even vision retaining.New therapeutic techniques including supra-selective ophthalmic artery interventional chemotherapy and intravitreal chemotherapy can further improve the efficacy of treatment,especially the eye salvage rate.The overall level of RB treatment should be improved by promoting the international staging,new therapeutic techniques,and the sequential multiple modality treatment.